Wall Street analysts expect Archer Daniels Midland (ADM) to post quarterly earnings of $0.83 per share in its upcoming report, which indicates a year-over-year decline of 27.2%. Revenues are expected to be $22.31 billion, up 3.8% from the year-ago quarter.The current level reflects a downward revision of 22.2% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Befo ...

Core Viewpoint - Analysts forecast that Abbott (ABT) will report quarterly earnings of $1.50 per share, reflecting an 11.9% year-over-year increase, with revenues expected to reach $11.79 billion, a 7.5% increase compared to the previous year [1]. Revenue and Earnings Estimates - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analysts' projections [1]. - Revisions to earnings projections are crucial for predicting investor behavior and stock performance [2]. Specific Metric Forecasts - Analysts predict 'Net sales- Nutrition' will reach $2.20 billion, marking a 3.3% increase year-over-year [3]. - 'Net sales- Diagnostics' is estimated at $2.54 billion, reflecting a 0.8% year-over-year change [4]. - 'Net sales- Medical Devices' is expected to be $5.68 billion, indicating a 12.5% increase from the prior year [4]. - 'Net sales- Medical Devices- Diabetes Care' is projected at $2.15 billion, showing a 15.5% increase year-over-year [4]. Regional Sales Insights - 'Net sales- Nutrition- International' is expected to reach $1.30 billion, a year-over-year increase of 8.2% [5]. - 'Net sales- Nutrition- U.S.' is projected at $897.76 million, indicating a decline of 3.3% year-over-year [5]. - 'Net sales- Diagnostics- International' is estimated at $1.50 billion, reflecting a 2.5% increase [6]. - 'Net sales- Diagnostics- U.S.' is expected to be $1.04 billion, showing a decline of 1.9% year-over-year [6]. - 'Geographic Revenue- U.S.' is projected to reach $4.56 billion, indicating a 5.1% increase [6]. Medical Devices Segment - 'Net sales- Medical Devices- U.S.' is forecasted at $2.62 billion, reflecting an 11.2% increase year-over-year [7]. - 'Net sales- Medical Devices- International' is expected to be $3.07 billion, indicating a 13.7% increase [7]. - 'Net sales- Medical Devices- Electrophysiology- International' is projected at $407.87 million, showing an 18.9% increase from the prior year [7]. Stock Performance - Abbott shares have decreased by 1.3% over the past month, contrasting with the Zacks S&P 500 composite's increase of 2% [8]. - Abbott holds a Zacks Rank 3 (Hold), suggesting it is expected to closely follow overall market performance in the near term [8].

Core Insights - Archer Daniels Midland Company (ADM) reported third-quarter 2025 results with revenues falling short of estimates but showing a year-over-year increase, while earnings exceeded estimates but declined compared to the previous year [1][2]. Financial Performance - Adjusted earnings were 92 cents per share, surpassing the Zacks Consensus Estimate of 89 cents, but down from $1.09 per share in the same quarter last year [2]. - Reported earnings were 22 cents per share, up from 4 cents in the year-ago quarter [2]. - Revenues increased by 2.2% year over year to $20.4 billion, missing the consensus estimate of $20.7 billion [2]. Segment Performance - Ag Services & Oilseeds revenues rose 3.5% year over year to $15.6 billion, while Carbohydrate Solutions revenues fell 5.9% to $2.7 billion, and Nutrition revenues increased 4.6% to $1.92 billion [3]. - Revenues from Other Business remained flat at $109 million compared to the prior year [3]. Profitability Metrics - Gross profit decreased by 7% year over year to $1.3 billion, with a gross margin of 6.2% [4]. - Selling, general and administrative expenses declined to $873 million from $905 million in the previous year [4]. - Adjusted segmental operating profit was $845 million, down 19% from the year-ago quarter [4]. Segmental Operating Profit Analysis - Adjusted operating profit for Ag Services & Oilseeds dropped 21% year over year to $379 million, despite a 78% increase in the Ag Services subsegment's operating profit [5]. - Crushing subsegment's operating profit plummeted 93% year over year due to lower margins and muted demand [6]. - Carbohydrate Solutions segment reported an operating profit of $336 million, reflecting a 26% decline from the previous year [8]. - Nutrition segment's operating profit increased by 24% to $130 million, with Human Nutrition subsegment gaining 12% year over year [11]. Financial Position - As of September 30, 2025, ADM had cash and cash equivalents of $1.24 billion, long-term debt of $7.6 billion, and shareholders' equity of $22.5 billion [13]. - The company generated $5.77 billion in cash from operating activities and paid out dividends of $743 million during the first nine months of 2025 [13]. Guidance Revision - For 2025, ADM revised its full-year adjusted EPS guidance to a range of $3.25 to $3.50 per share, down from the previous estimate of approximately $4.00 [14].

Core Insights - Archer Daniels Midland (ADM) is expected to report quarterly earnings of $0.88 per share, reflecting a year-over-year decline of 19.3% [1] - Revenue projections stand at $20.65 billion, indicating a 3.6% increase from the previous year [1] - Analysts have adjusted the consensus EPS estimate downward by 11.1% over the past 30 days, indicating a reassessment of initial projections [1] Revenue Projections - 'Revenues- Carbohydrate Solutions' are projected to reach $2.92 billion, a change of +0.5% year-over-year [4] - 'Revenues- Other Business' are expected to be $109.50 million, also reflecting a +0.5% change [4] - 'Revenues from external customers- Nutrition- Animal Nutrition' are estimated at $841.40 million, indicating a +1.7% change [5] - 'Revenues- Nutrition' are forecasted to be $1.88 billion, suggesting a +2.7% change [5] - 'Revenues- Ag Services and Oilseeds' are projected at $15.74 billion, reflecting a +4.3% change [5] - 'Revenues from external customers- Carbohydrate Solutions- Vantage Corn Processors' are expected to be $721.89 million, indicating a +0.8% change [6] - 'Revenues from external customers- Ag Services and Oilseeds- Crushing' are forecasted to reach $2.96 billion, a +3.2% change [6] - 'Revenues from external customers- Ag Services and Oilseeds- Refined Products and Other' are estimated at $2.77 billion, suggesting a +7.8% change [7] - 'Revenues from external customers- Carbohydrate Solutions- Starches and Sweeteners' are projected to be $2.20 billion, indicating a +0.4% change [7] - 'Revenues from external customers- Nutrition- Human Nutrition' are expected to reach $1.04 billion, reflecting a +3.5% change [8] - 'Revenues from external customers- Ag Services and Oilseeds- Ag Services' are projected at $10.01 billion, indicating a +3.7% change [8] Processed Volumes - Processed volumes for 'Oilseeds' are expected to be 8620 thousand metric tons, an increase from 8410 thousand metric tons reported in the same quarter last year [9] Stock Performance - Over the past month, ADM shares have recorded a return of +2.7%, outperforming the Zacks S&P 500 composite's +2.1% change [10] - ADM holds a Zacks Rank 4 (Sell), suggesting it may underperform the overall market in the upcoming period [10]

Core Insights - Perrigo Company plc is identified as one of the most oversold healthcare stocks in 2025, focusing on high-growth, high-margin categories in North America and Europe [2] Financial Performance - In Q2 2025, Perrigo reported net sales of $1.06 billion, reflecting a 0.9% decline year-over-year due to divestitures and exited products, particularly in infant formula and digestive health [3] - The company is experiencing soft seasonal demand in allergy, sun care, and blister care categories, along with a slower-than-expected recovery in infant formula [3] Strategic Initiatives - Perrigo is implementing a "Three-S" strategy—Stabilize, Streamline, and Strengthen—by divesting non-core assets, including the Dermacosmetics business, which is expected to close in Q1 2026 [4] - This strategy aims to streamline operations, reinforce the balance sheet, accelerate debt reduction, and enable a greater focus on its core self-care portfolio [4] Operational Enhancements - The company is enhancing operations through a global operating model upgrade and strengthened brand-building capabilities, contributing to market share gains in key segments [5] - Perrigo is emphasizing innovation and expansion in pain and sleep aids, nutrition, and upper respiratory products, aligning resources with higher-growth categories [5]

Core Insights - Abbott reported revenue of $11.14 billion for the quarter ended June 2025, reflecting a 7.4% increase year-over-year and a surprise of +0.63% over the Zacks Consensus Estimate of $11.07 billion [1] - The earnings per share (EPS) was $1.26, up from $1.14 in the same quarter last year, with an EPS surprise of +0.8% compared to the consensus estimate of $1.25 [1] Financial Performance Metrics - Net sales in Diagnostics (U.S.) were $811 million, slightly below the average estimate of $832.19 million, showing a year-over-year change of -0.1% [4] - International Nutrition net sales were $1.26 billion, matching the average estimate and reflecting a year-over-year increase of +3.1% [4] - U.S. Nutrition net sales reached $957 million, below the average estimate of $985.2 million, with a year-over-year increase of +2.6% [4] - International Diagnostics net sales were $1.36 billion, slightly below the average estimate of $1.38 billion, showing a year-over-year decline of -1.5% [4] - Established Pharmaceuticals net sales were $1.38 billion, exceeding the average estimate of $1.37 billion, with a year-over-year increase of +6.9% [4] - Total Diagnostics net sales were $2.17 billion, below the average estimate of $2.22 billion, reflecting a year-over-year change of -1% [4] - Medical Devices in Diabetes Care reported net sales of $1.98 billion, surpassing the average estimate of $1.94 billion, with a significant year-over-year increase of +20.2% [4] - Total Nutrition net sales were $2.21 billion, slightly below the average estimate of $2.24 billion, with a year-over-year increase of +2.9% [4] - Medical Devices in Structural Heart reported net sales of $636 million, below the average estimate of $643.65 million, with a year-over-year increase of +12.8% [4] - Heart Failure Medical Devices net sales were $368 million, exceeding the average estimate of $350.99 million, reflecting a year-over-year increase of +14.6% [4] - Electrophysiology Medical Devices net sales reached $700 million, surpassing the average estimate of $671.21 million, with a year-over-year increase of +11.6% [4] - Vascular Medical Devices net sales were $757 million, slightly above the average estimate of $754.03 million, with a year-over-year increase of +4.6% [4] Stock Performance - Abbott's shares have returned -0.5% over the past month, while the Zacks S&P 500 composite has increased by +4.2% [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

Core Insights - Archer Daniels Midland (ADM) reported a revenue of $20.18 billion for the quarter ended March 2025, which is a decrease of 7.7% compared to the same period last year [1] - The earnings per share (EPS) for the quarter was $0.70, down from $1.46 in the year-ago quarter, with a surprise of +1.45% against the consensus estimate of $0.69 [1] Financial Performance - The reported revenue fell short of the Zacks Consensus Estimate of $20.69 billion, resulting in a surprise of -2.51% [1] - ADM's stock has returned +10.5% over the past month, compared to the Zacks S&P 500 composite's +11.5% change, indicating a performance in line with the broader market [3] Segment Performance - Processed volumes for Oilseeds were reported at 9,091 Kmt, slightly below the average estimate of 9,152.33 Kmt [4] - Revenue from Carbohydrate Solutions was $2.57 billion, compared to the estimated $2.70 billion, reflecting a -4.2% change year-over-year [4] - Revenue from Ag Services and Oilseeds was $15.68 billion, below the average estimate of $16.07 billion, representing a -9% year-over-year change [4] - Nutrition segment revenue was $1.82 billion, slightly below the estimated $1.85 billion, with a -1% change compared to the previous year [4] - Adjusted segment operating profit for Carbohydrate Solutions was $240 million, exceeding the average estimate of $224.98 million [4] - Adjusted segment operating profit for Nutrition was $95 million, significantly higher than the average estimate of $43.30 million [4] - Adjusted segment operating profit for Ag Services and Oilseeds was $412 million, below the average estimate of $454.27 million [4]